Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 375

Similar articles for PubMed (Select 23562641)

2.

Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.

El-Gazzaz G, Sourianarayanane A, Menon KV, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F.

Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):34-41.

3.

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.

Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ.

Radiology. 2012 Feb;262(2):708-18. doi: 10.1148/radiol.11110282. Epub 2011 Dec 20.

PMID:
22187634
4.

EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.

Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.

Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.

5.

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.

J Hepatol. 2013 Jun;58(6):1181-7. doi: 10.1016/j.jhep.2013.01.039. Epub 2013 Feb 8.

PMID:
23395691
6.
7.

Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma.

Vogl TJ, Naguib NN, Nour-Eldin NE, Farshid P, Lehnert T, Gruber-Rouh T, Engels KS.

Acad Radiol. 2012 Apr;19(4):434-9. doi: 10.1016/j.acra.2011.12.009. Epub 2012 Jan 23.

PMID:
22265853
8.

Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.

Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC, Durham J.

J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.

PMID:
24060436
9.

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T.

J Hepatol. 2011 Dec;55(6):1309-16. doi: 10.1016/j.jhep.2011.03.007. Epub 2011 Apr 15.

PMID:
21703196
10.

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB 3rd, Nemcek AA Jr, Omary R, Salem R.

JAMA. 2010 Mar 17;303(11):1062-9. doi: 10.1001/jama.2010.262.

11.

Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.

Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.

Radiology. 2014 Mar;270(3):747-57. doi: 10.1148/radiol.13130591. Epub 2013 Dec 12.

PMID:
24475816
12.

Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.

Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.

J Vasc Interv Radiol. 2014 Feb;25(2):248-55.e1. doi: 10.1016/j.jvir.2013.10.017. Epub 2013 Dec 2.

PMID:
24295569
13.

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C.

Radiology. 2012 Oct;265(1):115-23. Epub 2012 Aug 13.

14.

Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.

Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.

J Vasc Interv Radiol. 2013 Mar;24(3):316-25. doi: 10.1016/j.jvir.2012.10.022. Epub 2013 Jan 9.

PMID:
23312990
15.

Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.

Yeo DM, Choi JI, Lee YJ, Park MY, Chun HJ, Lee HG.

J Comput Assist Tomogr. 2014 May-Jun;38(3):391-7. doi: 10.1097/RCT.0000000000000070.

PMID:
24681857
16.

Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.

Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.

Cardiovasc Intervent Radiol. 2012 Feb;35(1):82-9. doi: 10.1007/s00270-010-0086-6. Epub 2011 Jan 4.

PMID:
21203761
17.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.

Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20.

18.

Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.

Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.

Radiology. 2013 Aug;268(2):431-9. doi: 10.1148/radiol.13121637. Epub 2013 Apr 24.

PMID:
23616632
19.

Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma.

Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W.

Liver Transpl. 2007 Feb;13(2):272-9.

20.

Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival.

Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R.

Can J Gastroenterol. 2011 Aug;25(8):426-32.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk